Articles Mentioning Defensive Stocks

Results 1 - 10 of 119 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Defensive

Investing | December 19, 2014

The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?

In this week's Industry Focus, our analysts discuss their favorites of the successful 2014 healthcare large-cap stocks.

Investing | December 08, 2014

Is It Time to Buy This Growth Stock?

Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?

Investing | December 07, 2014

The 3 Most Memorable Moments in Healthcare This Year

Three Motley Fool analysts tell investors what they believe are the year's most memorable events in the healthcare sector.

Investing | November 25, 2014

Should Allergan Investors Stick With Actavis?

Just because you own Allergan doesn't mean you should necessarily own Actavis.

Investing | November 12, 2014

5 Things Actavis plc's Management Wants You to Know

Specialty and generic drugmaker Actavis plc reported another monster quarter last week. Here are five things management wants investors to know going forward.

Investing | November 11, 2014

Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?

Valeant Pharmaceuticals' takeover bid for Allergan has turned hostile in more ways than one.

Investing | November 05, 2014

Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza

Actavis posted third-quarter earnings this morning. Here's what you need to know.

Investing | October 02, 2014

Why Allergan Inc. Is an Activist Investor Target

Botox-maker Allergan has attracted activist investors in droves lately. Here's why.

Investing | July 05, 2014

This Week in Biotech: Allergan Three-Peats in a Bad Way While Agenus Impresses

An early FDA approval, an inhaled therapy being turned away by regulators for a third time, and three positive clinical updates are this week's top biotech stories.

Investing | February 05, 2014

Valeant's Inorganic Growth Could Threaten These 3 Companies in 2014

Valeant just made its first acquisition of the year. Let’s take a closer look at three companies -- Allergan, Actavis, and Zeltiq -- which could be threatened by the company’s inorganic growth.

Results 1 - 10 of 119 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Defensive